12th International PGD Conference, Istanbul, 8-11 May 2013
Scientific Program

Day 1 MAY 8, 3 PARALLEL WORKSHOPS:

Array-CGH

Gamete and embryo vitrification

Time lapse imaging and blastocyst culture for embryo selection

Day 2 MAY 9, PLENARY LECTURE AND SESSIONS 1-4

1. Controlled Ovarian Stimulation in PGD

   1.1 Effect on aneuploidy rates?

   1.2 Effect on endometrial receptivity?

   1.3 Are there special regiments for different PGD indications?

2. Technical Aspect of PGD

   2.1 Choices of Biopsy procedures, their impact on embryo viability and PGD accuracy:

      2.1.1 Polar Body Sampling, Cleavage Stage or Blastocyst Biopsy or Combination?

      2.1.2 Laser, Acid Tyrode's or mechanical?

      2.1.3 Do we need more data on effect of biopsy procedures, different media and culture
      conditions on embryo viability?

      2.1.4 Expanding Use of Vitrification - any risk for epigenetic effect?

      2.1.5 Quality Assessment and Quality Control

2.2 Genetic Analysis:

   2.2.1 Do we still need FISH for PGD of aneuploidy and translocations?

   2.2.2 Array-CGH - Advantages/Disadvantages/Validation

   2.2.3 SNP-array - Advantages/Disadvantages/Validation

   2.2.4 Real Time PCR - Advantages/Disadvantages/Validation

   2.2.5 Prospect of Next generation sequencing in PGD

Sessions 3 & 4 ORAL COMMUNICATIONS
Day 3 MAY 10, SESSIONS 5-8

5. Reproductive outcome of preimplantation aneuploidy testing

5.1 Biological Evidence for Expected Positive Impact of PGD for Aneuploidy:

5.1.1 Evidence from Female Meiosis
5.1.2 Evidence from Male Meiosis
5.1.3 Is there Any New Data on Mechanisms of Aneuloidy?
5.1.4 Evidence from Animal Data

5.2 Clinical Evaluation of Aneuploidy Testing Outcome

5.2.1 Why Expected Benefit Not Observed in Previous Randomized Controlled Studies
5.2.2 Reproductive Outcome of Aneuploidy Testing Depending on Biopsy Procedure and Microarray Technology Application
5.2.3 Results of Randomized Controlled Studies Using Microarray Technology

5.3 PGD Safety - Comparative Prevalence of Congenital Anomalies Following PGD & ART

6. Place of PGD in endemic areas for common genetic disorders of public health importance

Progress Reports from Selected Populations on Reduction of Endemic Genetic Disorders Using Community Based Preventive Programs of Population Screening and Prenatal Diagnosis

7 & 8 ORAL COMMUNICATIONS

Day 4 MAY 11, SESSIONS 9 & 10

9. Expanding PGD Indications

9.1 PGD for Genetic Predisposition for Common Disorders
9.2 PGD for HLA: Clinical Outcome of HLA Compatible Transplantation following PGD, including post HLA Typing
9.3 Comprehensive PGD for Multiple Indications
9.4 PGD Accuracy and Quality Control

10. PGD Future

10.1 Alternatives to PGD
10.2 Non-invasive assessment of oocytes and embryos

10.3 Testing for cytoplasmic abnormalities

10.4 Prospect of testing for genetic expression disorders

May 12-14 Post-Congress Hands-On Workshop on PGD for genetic and chromosomal disorders using different biopsy procedures.